Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Gynecologic 3Tumor-Agnostic 2Genitourinary 2Sarcoma 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × berzosertib × Head & Neck × Clear all
NCT02567422 2026-06-02

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
43 enrolled 16 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡